HomeCompareABBV vs AWR

ABBV vs AWR: Dividend Comparison 2026

ABBV yields 3.12% · AWR yields 2.58%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AWR wins by $79.8K in total portfolio value· pulled ahead in Year 8
10 years
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →
AWR
AWR
● Live price
2.58%
Share price
$76.72
Annual div
$1.98
5Y div CAGR
51.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$184.5K
Annual income
$83,320.36
Full AWR calculator →

Portfolio growth — ABBV vs AWR

📍 AWR pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodABBVAWR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ABBV + AWR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ABBV pays
AWR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
AWR
Annual income on $10K today (after 15% tax)
$219.09/yr
After 10yr DRIP, annual income (after tax)
$70,822.31/yr
At 15% tax rate, AWR beats the other by $48,955.44/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ABBV + AWR for your $10,000?

ABBV: 50%AWR: 50%
100% AWR50/50100% ABBV
Portfolio after 10yr
$144.6K
Annual income
$54,523.04/yr
Blended yield
37.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
AWR
Analyst Ratings
2
Buy
5
Hold
3
Sell
Consensus: Hold
Price Target
$89.50
+16.7% upside vs current
Range: $87.00 — $92.00
Altman Z
1.9
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ABBV buys
7
AWR buys
0
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricABBVAWR
Forward yield3.12%2.58%
Annual dividend / share$6.65$1.98
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR40.6%51.3%
Portfolio after 10y$104.7K$184.5K
Annual income after 10y$25,725.73$83,320.36
Total dividends collected$63.0K$153.5K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusBuyHold
Analyst price target$256.15$89.50

Year-by-year: ABBV vs AWR ($10,000, DRIP)

YearABBV PortfolioABBV Income/yrAWR PortfolioAWR Income/yrGap
1$11,559$438.51$11,090$389.98+$469.00ABBV
2$13,494$640.86$12,478$611.55+$1.0KABBV
3$15,951$945.97$14,324$972.96+$1.6KABBV
4$19,152$1,413.89$16,906$1,579.37+$2.2KABBV
5$23,443$2,146.38$20,726$2,635.82+$2.7KABBV
6$29,391$3,321.96$26,745$4,569.09+$2.6KABBV
7$37,948$5,265.87$36,955$8,337.34+$993.00ABBV
8← crossover$50,795$8,596.74$55,831$16,289.43$5.0KAWR
9$71,034$14,549.41$94,538$34,798.89$23.5KAWR
10$104,715$25,725.73$184,476$83,320.36$79.8KAWR

ABBV vs AWR: Complete Analysis 2026

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →

AWRStock

American States Water Company, through its subsidiaries, provides water and electric services to residential, commercial, industrial, and other customers in the United States. It operates through three segments: Water, Electric, and Contracted Services. The company purchases, produces, distributes, and sells water, as well as distributes electricity. As of December 31, 2021, American States Water Company provided water service to 262,770 customers located throughout 10 counties in the State of California; and distributed electricity to 24,656 customers in San Bernardino County mountain communities in California. The company also provides water and/or wastewater services, including the operation, maintenance, and construction of facilities at the water and/or wastewater systems at various military installations. American States Water Company was incorporated in 1929 and is based in San Dimas, California.

Full AWR Calculator →
📬

Get this ABBV vs AWR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ABBV vs JNJABBV vs MRKABBV vs PFEABBV vs BMYABBV vs LLYABBV vs SCHDABBV vs JEPIABBV vs O

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.